FindTrial
Sign In

Analysis of blood concentration of hydroxychloroquine to predict its efficacy and safety to treat Japanese patients with rheumatoid arthritis.

Analysis of blood concentration of hydroxychloroquine to predict its efficacy and safety to treat Japanese patients with rheumatoid arthritis. - Analysis of blood concentration of hydroxychloroquine to predict its efficacy and safety to treat Japanese patients with rheumatoid arthritis.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000054613
Enrollment
60
Registered
2024-06-09
Start date
2023-06-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Sponsors

Keio University School of medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were enrolled in "Efficacy and safety of hydroxychloroquine for Japanese patients with rheumatoid arthritis (N20140489)" and whose sera were preserved.

Exclusion criteria

Exclusion criteria: Ineligible for the study judged by physicians

Design outcomes

Primary

MeasureTime frame
association between efficacy and safety of HCQ and its blood concentration—

Countries

Japan

Contacts

Public ContactYuko Kaneko

Keio University School of Medicine Division of Rheumatology

ykaneko.z6@keio.jp03-5363-3786

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026